Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 3/20 | 0.36 |
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930549 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL28600193 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL14771517 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL13952067 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL9550769 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL13901245 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL22984007 | 1.00 | RNASE1 (0.40) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL14770137 | 0.99 | RNASE1 (0.39) | RNASE1TK1TK2TYMSTOP2A | |
| SCHEMBL8654714 | 0.95 | RNASE1 (0.43) | RNASE1TK1TK2TYMP | |
| SCHEMBL24263898 | 0.94 | TYMS (0.35) | RNASE1TK1TYMSTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496335-B | Modified nucleotide and application thereof | 中国药科大学 | 2024-03-08 | — | — | CN | claimed |
| CN-116496335-A | Modified nucleotide and application thereof | 中国药科大学 | 2023-07-28 | — | — | CN | claimed |
| CN-116411354-A | Gene chip with modified surface of solid phase carrier | 深圳华大生命科学研究院 | 2023-07-11 | — | — | CN | claimed |
| CN-113150041-B | Preparation method of thiooligonucleotide | 北京悦康科创医药科技股份有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-4745240-A2 | SIRNA FOR TARGETED INHIBITION OF AGT GENE EXPRESSION AND USE THEREOF IN TREATING HYPERTENSION | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260125413-A1 | UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12595500-B2 | High efficiency, small volume nucleic acid synthesis | Life Technologies Corporation (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260085317-A1 | SIRNA FOR TARGETED INHIBITION OF AGT GENE EXPRESSION AND USE THEREOF IN TREATING HYPERTENSION | HANGZHOU TIANLONG PHARMACEUTICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| EP-4709857-A1 | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE | Astrazeneca AB (SE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695265-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20260001904-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORP (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4605403-B1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-6114519-A | PHOSPHITYLATION; OXIDATION ACYL DISULFIDE | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6040438-A | Reagent useful for synthesizing sulfurized oligonucleotide analogs | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5902881-A | Reagent useful for synthesizing sulfurized oligonucleotide analogs | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| US-5866691-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5714597-A | Use of carbocation scavenger during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5510476-A | SOLID PHASE SYNTHESIS USING AN ACIDIC SOLUTION OF THE SCAVENGER TO DEPROTECT THE 5'-HYDROXY AND NEUTRALIZE THE CARBO ANION RELEASED; HIGH YIELDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5218102-A | Easily synthesized, hybridize well with target sequences | IMPROBIO (BE) | 1993-06-08 | — | — | US | disclosed |
| EP-0334694-A1 | Nucleic acid probes with non-radioactive labels, and preparation processes | LA REGION WALLONNE (BE) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001904-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLR2E, NSUN2 | RNASE1 358/4885TK1 86/4885TK2 280/4885 |
| US-12595500-B2 | High efficiency, small volume nucleic acid synthesis | POLM, POLQ, POLRMT | RNASE1 437/4885TK1 621/4885TK2 220/4885 |
| US-20260085317-A1 | SIRNA FOR TARGETED INHIBITION OF AGT GENE EXPRESSION AND USE THEREOF IN TREATING HYPERTENSION | AGT, AGTR1, AGTR2 | RNASE1 52/4885TK1 328/4885TK2 686/4885 |
| US-20260125413-A1 | UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | SSU72, NSUN2, POLR2H | RNASE1 1172/4885TK1 46/4885TK2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.